Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | Inquiry | 1-2 weeks | |
50 mg | Inquiry | 1-2 weeks | |
100 mg | Inquiry | 1-2 weeks |
Description | Varenicline (CP 526555), a cytisine-based nicotinic ligand, is a potent partial agonist for the α4β2 nicotinic acetylcholine receptor (nAChR) with an EC50 value of 2.3 μM and acts as a full agonist for α7 and α3β4 nAChRs, with respective EC50 values of 18 μM and 55 μM [1]. Notably, its effectiveness and potential in smoking cessation treatments are underscored by its pharmacological profile [2]. |
In vivo | Varenicline (CP 526555) (subcutaneous injection; 0.01, 0.05, 0.1 and 1 mg/kg; 3 days) iven 10 min prior to nicotine, dose-dependently inhibits nicotine CPP. At the doses of 0.1 and 1 mg/kg totally blocks the effect of nicotine in CPP test without inducing significant changes in preferences on their own [2].Varenicline (2.5 mg/kg) results in a place aversion that was dependent on α5 nAChRs but not β2 nAChRs [2].Varenicline (0.1 and 0.5 mg/kg) reverses nicotine withdrawal signs such as hyperalgesia and somatic signs and withdrawal-induced aversion in a dose-related manner [2]. Animal Model: ICR male mice (8 weeks) [1] Dosage: 0.01, 0.05, 0.1 and 1 mg/kg Administration: 3 days Result: Supressed the effect of nicotine in CPP test. |
Molecular Weight | 211.26 |
Formula | C13H13N3 |
Cas No. | 249296-44-4 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.